Question · asked by 1 review
Orlistat vs placebo: Serious adverse events
- Population
- Men and non‐pregnant women ≥ 18 years old with essential hypertension
- Intervention
- Orlistat
- Comparison
- placebo
- Outcome
- Serious adverse events
Orlistat probably leads to higher serious adverse events compared with placebo (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Orlistat vs placebo Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension Orlistat probably leads to higher serious adverse events compared with placebo (moderate certainty). Long‐term effects of weight‐reducing drugs in people with hypertension (2021) · Cochrane Headline outcomes only | RR 1.45 [1.1, 1.91] | 3 studies · 1476 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.